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Abstract
Multivariate biomarkers that can predict the effectiveness of targeted therapy in individual
patients are highly desired. Previous biomarker discovery studies have largely focused on
the identification of single biomarker signatures, aimed at maximizing prediction accuracy.
Here, we present a different approach that identifies multiple biomarkers by simultaneously
optimizing their predictive power, number of features, and proximity to the drug target in a
protein-protein interaction network. To this end, we incorporated NSGA-II, a fast and elitist
multi-objective optimization algorithm that is based on the principle of Pareto optimality, into
the biomarker discovery workflow. The method was applied to quantitative phosphopro-
teome data of 19 non-small cell lung cancer (NSCLC) cell lines from a previous biomarker
study. The algorithm successfully identified a total of 77 candidate biomarker signatures
predicting response to treatment with dasatinib. Through filtering and similarity clustering,
this set was trimmed to four final biomarker signatures, which then were validated on an in-
dependent set of breast cancer cell lines. All four candidates reached the same good pre-
diction accuracy (83%) as the originally published biomarker. Although the newly
discovered signatures were diverse in their composition and in their size, the central protein
of the originally published signature— integrin β4 (ITGB4)— was also present in all four
Pareto signatures, confirming its pivotal role in predicting dasatinib response in NSCLC cell
lines. In summary, the method presented here allows for a robust and simultaneous identifi-
cation of multiple multivariate biomarkers that are optimized for prediction performance,
size, and relevance.
Introduction
Targeted drugs, such as kinase inhibitors, are extensively studied as promising agents either
alone or in combination with other agents for treating cancer. Unfortunately, only subsets of
patients usually respond to targeted therapeutic interventions. Tests that can predict whether
patients will benefit from these therapies are therefore desired companions of targeted drugs.
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Many, if not all response prediction tests currently used in clinical practice are based on mark-
ers directly linked to the disease-relevant drug target. However, singleton markers measuring
the expression or mutation status of a drug target may often not be sufficient to predict re-
sponse. For example, it has recently been shown that the success of predicting how melanomas
respond to targeted therapies by genotyping alone may be limited [1].
Therefore, several studies have focused on identifying molecular signatures comprising multi-
ple markers for response prediction. Predominantly, these signatures were identified using tran-
scriptomics data (for example [2, 3]). In recent years, advances in sample processing, mass
spectrometry, and computer algorithms for the analyses of proteomics data have enabled the ap-
plication of mass spectrometry-based proteomics in order to monitor phosphorylation events in
a global and unbiased manner [4–6]. These methods have become sufficiently sensitive and ro-
bust to identify and quantify thousands of phosphorylation sites in a single experiment. Phos-
phorylation events play an important role in transduction of signals caused by external stimuli
from the cell membrane to the nucleus. Aberrations of these signal transduction pathways are
important for the understanding of the molecular mechanism of various diseases, such as cancer,
inflammation, and diabetes [7, 8]. At the same time, many of the targeted therapies interfere with
these kinase signaling pathways. Consequently, multivariate markers based on the phosphoryla-
tion status of certain sets of proteins—here referred to as phospho-signatures—are assumed to
reliably predict the clinical response. This has been demonstrated in two recent studies, where
phosphoproteomics data was used to identify predictive multivariate markers for the multi-ki-
nase inhibitor dasatinib [9] and the FLT3 inhibitor quizartinib [10].
Previous studies have focused on the identification of one single multivariate marker signa-
ture that was optimized for prediction accuracy. Here, we investigate a method that allows for
the incorporation of additional objectives that are optimized simultaneously, and enables the
identification of several predictive marker signatures. Such objectives can, for instance, be relat-
ed to the annotations of protein markers (e.g. localization, function), to technical properties
(e.g. size of the signature), or to network information (e.g. proximity of markers to drug target).
Recently, it has been shown in a study analyzing 44 drug sensitivity prediction algorithms that
the impact of including annotated biological information is stronger than the impact of the
method category (e.g. support vector machine, random forest, etc.) or the method for missing
data handling [11]. More specifically, it has also been demonstrated that adding network infor-
mation can improve prediction accuracy or at least improve the robustness of feature selection
(e.g. [12]). These methods have in common that the network information is factored in by
modifying the objective function (e.g. network-based support vector machines [13]) or the
rank order for filter-based feature selection (e.g. NetRank [14, 15]). However, instead of opti-
mizing a combined objective function, we choose to optimize multiple objectives in parallel
using principles of multi-objective or, specifically, Pareto optimization [16]. Multi-objective
optimization methods return a set of optima, the so-called Pareto front, instead of a single opti-
mum solution. In case of selection of predictive biomarkers, these solutions differ in their com-
position of selected features and in the degree to which different objectives are optimized. If
necessary to limit the number of marker candidates, the researcher can apply post hoc weight-
ing of objectives.
In biomedical research, Pareto optimization has been mainly applied to design of small mol-
ecules [17] and peptide sequences [18]. More recently however, it has also been applied to se-
lection of features. For example, Rajapakse and Mundra optimized features for multi-class
classification by decomposing the over-all objective to multiple objectives for each pair of clas-
ses [19]. Xue et al. complemented the objective of classification accuracy with minimizing the
size of the signature [20]. Here, we generalize the idea of applying Pareto optimization to the
problem of selecting predictive marker signatures by optimizing not only the prediction
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accuracy and the size of the signature, but also the biological relevance of the selected features.
We define the biological relevance by the proximity of features to the respective drug target as
derived from protein-protein interaction networks. In principle, all obtained solutions on the
Pareto front can be evaluated and tested in validation experiments. However, since in practice
the Pareto front consists of several dozens of solutions, we propose to cluster these solutions in
feature space and investigate a much smaller number of cluster centroids. We apply the pro-
posed method to the identification of multivariate phosphorylation signatures that predict re-
sponse to dasatinib in non-small cell lung cancer and breast cancer cell lines using the
phosphoproteomics data generated by Klammer et al. [9].
Results and Discussion
The main goal of response prediction biomarker studies is the identification of molecular sig-
natures that separate the group of responders from the group of non-responders well and thus
enable an accurate prediction of drug response. However, there are further qualities that char-
acterize a successful biomarker. For example, a marker should consist of a manageable number
of features (i.e. genes or proteins) in order to allow testing through methods applied in clinical
routine such as quantitative PCR or ELISA. Furthermore, the features should be biologically
relevant, for instance, by being connected to the drug’s target or mechanism of action. In the
proposed Pareto biomarker workflow, these three objectives—separation, signature size and
relevance—are optimized in parallel (for definitions of objectives see section Pareto objective
functions in Materials and Methods).
Pareto biomarker workflow
To this end, a multi-objective optimization algorithm (MOA) was incorporated into our estab-
lished biomarker discovery workflow [9], allowing the simultaneous optimization of all three
objectives. Most MOAs employ the principle of Pareto optimality, which aims at detecting so-
lutions that are not dominated by other solutions. At any given iteration, non-dominated solu-
tions are defined such that there exist no other solutions that have a better or equal score in all
objectives and a strictly better score in at least one objective. All non-dominated solutions (Pa-
reto points) together form the Pareto front (see also S1 Fig), which is optimized during each it-
eration. Of the many MOA algorithms available (e.g. PAES [21], PESA [22], SPEA2 [23],
NSGA-II [24] or SMS-EMOA [25]), we found the NSGA-II algorithm [24] most suitable
for our Pareto biomarker workflow, as it shows fast convergence, is efficient and well tested
[26, 27].
In a previous study, we used quantitative mass-spectrometry to globally profile the basal
phosphoproteome of a panel of 19 non-small cell lung cancer (NSCLC) cell lines [9]. The effect
of the kinase inhibitor dasatinib on cellular growth was tested against the same panel. Using
the phosphoproteome data, we identified a phosphorylation signature consisting of 12 phos-
phorylation sites on 9 different proteins. The signature accurately predicted response to treat-
ment with dasatinib in the NSCLC cell lines used for training and in an independent validation
panel of breast cancer cell lines.
Here, we investigated whether the Pareto biomarker workflow could confirm the original
signature and/or identify additional multivariate predictive phosphorylation signatures when
applied to the same data set. In particular, these signatures should not only maximize class sep-
aration, but also the two additional objectives signature size and relevance. We hypothesize that
if a marker protein is closely related to the drug target (e.g. through interaction), this protein is
more relevant in the sense that a signature consisting of such proteins will lead to more robust
predictions when applied to diverse sets of samples. Although this might not always be the
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case, we think that this is a good assumption on average. Since this is only one out of three ob-
jectives to be optimized, signatures that are not connected to the drug’s target may still be iden-
tified and are not discarded. More specifically, we define the relevance score of a signature as
the average distance of the signature’s proteins to dasatinib’s main target in solid tumors, the
Src kinase (SRC), as it has been shown that dasatinib inhibits migration and invasion of various
solid tumors through inhibition of SRC [28–30]. All three scores are defined such that smaller
values are better. Thus, all three objectives are to be minimized (see Materials and Methods for
details).
From the 4,457 phosphorylation sites quantified in at least 2/3 of the samples in each class
(responders and non-responders), we selected the 100 sites that discriminated best between re-
sponders and non-responders according to the MeanRank test [31], while ensuring that the
mean difference between the two groups was at least 4-fold and only one phosphosite per pro-
tein was taken. This pre-selection was performed to reduce the complexity of the subsequent
Pareto optimization. The algorithm terminated after 1353 generations, at which point the re-
sults on the first Pareto front had not changed for 200 generations (Fig 1). While the number
of solutions on the Pareto front constantly increased, the three objectives (i.e. separation, size
Fig 1. Evolution of the number of individuals (solutions) on the Pareto front and for the three objectives (separation, size and relevance), as
generated by the NSGA-II algorithm [24]. The objectives are averaged across the solutions on the Pareto front. The number of generations is binned and
the average of each bin is displayed on the y-axis.
doi:10.1371/journal.pone.0128542.g001
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and relevance) were minimized with respect to Pareto optimality. As can be deduced from the
graphs of the three objectives, the size and relevance criteria are rather easy to optimize, as they
exhibit a steep decline at the beginning of the optimization process and reach the global mini-
mum early on. Optimization of the separation criterion took longer and its decrease in the later
stages was accompanied with an increase of the size objective, while the relevance criterion re-
mained stable. In essence, small signatures that have a short distance to the drug target in the
STRING protein-protein interaction (PPI) are readily discovered. It is, however, harder to find
those that additionally separate the groups well and, essentially, good separation comes at the
cost of larger signatures.
After termination, 77 solutions were located on the Pareto front. Solutions with a separation
score −0.6 were removed (N = 24), as the Pareto approach also found very small and biologi-
cally relevant solutions with poor separation. This is an inherent feature of Pareto optimization,
and removing undesired solutions is common practice (see e.g. [32]). The remaining 53 solu-
tions contained 35 different phosphorylation sites. One site, S1148 on integrin β4 (ITGB4), was
part of all but three solutions.
Fig 2A shows a series of three-dimensional plots of the Pareto front. The front has the shape
of a stretched canvas attracted by the origin, which represents an ideal but infeasible point. Fig
2B depicts 2D projections of the 53 Pareto front solutions in objective space. The top panel, re-
lating size and separation, shows that smaller signatures lead to less pronounced separation
and illustrates our initial motivation for identifying multivariate markers. Therefore, the lower
left corner in the plot, where ideal solutions for the two respective objectives are expected, is
not populated. However, there are also no large signatures in the area of the best-separating so-
lutions (< −0.68). This is due to the third objective, the relevance criterion, as it becomes
harder to identify features that all interact directly or indirectly with the target. As mentioned
before, the task of finding small and biologically relevant solutions is achieved more easily, as
can be seen in the center panel of Fig 2B. Solutions are found in the lower left area, but not in
the lower right. The bottom panel of Fig 2B depicts the relationship between separation and
relevance. This projection of the Pareto front has a curved shape, revealing the compromise be-
tween good separation and biologically meaningful features, as not all well-discriminating
phosphosites are also related to the drug target.
Pareto signatures
Each of the identified solutions on the Pareto front is optimal in the sense that none of them
are dominated by any other solution. Therefore, each solution could be evaluated individually.
Here we took another approach and investigated whether solutions can be reduced by cluster-
ing according to their similarity while retaining discriminatory power. To this end, we hierar-
chically clustered the solution in features space using the Ward method and obtained four
major clusters (see Fig 3). For each of these clusters, the feature with the smallest Euclidean dis-
tance to the respective cluster centroid was selected as so-called Pareto signature for further
analysis (see Fig 2B).
In order to compare the original 12-phosphosite signature with the Pareto signatures, we
calculated its objective values: size = 12, separation = −0.60, relevance = 1.63 (see also Table 1).
Note, that the original signature was optimized with respect to prediction accuracy only, and
the feature selection method did not explicitly optimize the separation criterion as defined here
(see Materials and Methods). Fig 4A shows the PPI network of the original marker, where solid
lines indicate the shortest path from each signature phosphoprotein (blue) to SRC (red), which
is dasatinib’s main target in solid tumors. The phosphorylation sites of the signature are listed
in Table 2 (referred to as original signature). Some of the signature proteins ITGB4,
Identification of Predictive Pareto Biomarker Signatures
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ARHGEF18 and BAIAP2 are closely related to SRC, while others (e.g. ATG16L1 and
TNK1SBP1) have larger distances in the PPI network. TPD52L2 and GPRC5A have no con-
nection to SRC at all. In the original publication [9], the selected features were used to train a
support vector machine (SVM) with linear kernel. The signature and the corresponding pre-
dictor were then validated by application to six independent breast cancer cell lines, which had
not been used for feature selection or SVM training. In the case of the original signature, five
out of six cell lines were predicted correctly with an average probability distance to the hyper-
plane of 0.13 (calculated as 1
N
PN
i¼1ð0:5 piÞci, where N is the number of tested cell lines, pi the
prediction probability for the cell line to be resistant, and ci the actual class of the cell line (sen-
sitive = 1, resistant = −1)).
Fig 2. 3D plots of the Pareto front (A) and 2D projections (B). (A) The different panels are views of the Pareto front when rotated around the relevance-
axis (with two different viewing angles in both columns). Coloring indicates relevance score, from blue (low) to red (high). Since better solutions are smaller in
all three dimensions, the optimal point is the origin in the lower background, i.e. the only hidden vertex in the plots. (B) 2D projections of the solutions on the
Pareto front. Solutions are colored according to their assignment to four clusters. Stars mark the solutions closest to the respective cluster centroid that were
selected as final Pareto signatures.
doi:10.1371/journal.pone.0128542.g002
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The first Pareto signature (Pareto1, Fig 4B) contains only three phosphoproteins—ITGB4
(integrin β4) S1448, EGFR (epidermal growth factor receptor) S1064 and KIAA0556 (unchar-
acterized protein KIAA0556) S691—for details see Table 2. While the separation and size ob-
jective scores are better than those of the original signature (see Table 1), the relevance score is
slightly worse, which is due to the uncharacterized protein KIAA0556 that lacks functional an-
notation and therefore has no connection with SRC. The prediction accuracy on the validation
set is comparable to that of the original signature, however, the average probability distance to
the SVM hyperplane is slightly higher and thus better. Phosphorylation site S1448 on ITGB4 is
Fig 3. Hierarchical clustering of the 53 accepted solutions on the Pareto front in feature space. In each row, red areas represent features
(phosphosites) that are part of the corresponding solution. The solutions were subdivided into four clusters according to the row dendogram on the left.
Cluster numbers are indicated on the right.
doi:10.1371/journal.pone.0128542.g003
Table 1. Objective scores (smaller are better), prediction accuracy and average probability distance for the validation data (larger are better).
Signature Size Separation Relevance Validation accuracy Validation distance
Original 12 -0.60 1.63 5/6 0.13
Pareto1 3 -0.65 1.88 5/6 0.19
Pareto2 5 -0.63 0.72 5/6 0.22
Pareto3 3 -0.65 1.55 5/6 0.19
Pareto4 7 -0.67 1.26 5/6 0.15
doi:10.1371/journal.pone.0128542.t001
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Fig 4. Network of the original (A) and the four Pareto signatures (B-E) are shown in the left column along with the prediction results for the breast
cancer validation set (right column). Blue nodes in the network are signature proteins, solid lines represent the shortest path to SRC, dashed lines indicate
additional high-confidence interactions in the network. Sensitive (1–3) and resistant (4–6) breast cancer cell lines were considered to be predicted correctly if
they received a probability (y-axis) of less than 0.5, or more than 0.5, respectively.
doi:10.1371/journal.pone.0128542.g004
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one of the best separators in the data set and is also part of the original signature. ITGB4 is
linked to the Src-Fak pathway [33] and is associated with poor patient prognosis [34–36]. The
EGF receptor can be phosphorylated by the Src kinase [37], and is therefore directly linked to
SRC in the protein-protein interaction network (STRING confidence score of 0.999).
The signature Pareto2 (Fig 4C), contains the same phosphosites on ITGB4 and EGFR, and
additionally TANK (TRAF family member-associated NF-kappa-B activator) S225, TIAM1
(T-lymphoma invasion and metastasis-inducing protein 1) S231 and JUP (Junction plakoglo-
bin) S665—see also Table 2. This signature has a particularly good relevance score (cf. Table 1),
which is also visible in the PPI network, where 4 out of 5 proteins are closely connected to SRC.
The performance on the validation data is comparable to that of Pareto1.
The third Pareto signature (Pareto3, Fig 4D) is another small signature containing sites
S1448 on ITGB4, S20 on PLEC1 (Plectin) and S429 on TNKS1BP1 (182 kDa tankyrase-1-bind-
ing protein). S429 on TNKS1BP1 is also part of the original signature, together with S1448 on
Table 2. Phosphorylation sites of the final signatures. Sites/proteins in bold are part of the original signa-
ture [9].
Signature Accession Gene name Site












Pareto1 P16144-2 ITGB4 S1448
A9CB80 EGFR S1064
O60303 KIAA0556 S691





Pareto3 P16144-2 ITGB4 S1448
Q15149-4 PLEC1 S20
Q9C0C2 TNKS1BP1 S429
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ITGB4. TNKS1BP1 has a rather large distance to SRC, leading to a mediocre relevance score.
The other scores are identical to those of Pareto1, the second 3-phosphosite signature (cf.
Table 1).
Finally, the largest Pareto signature (Pareto4, Fig 4E), contains ITGB4 S1448, TNK1SBP1
S429, TJP2 (Tight junction protein ZO-2) S174, CGN (Cingulin) S137, SEPT9 (Septin-9) S30,
TIAM1 S231 and ITPR3 (Inositol 1,4,5-trisphosphate receptor type 3) S934. Again, the sites on
ITGB4 and TNKS1BP1 are those that are part of the original signature. ITPR3 appears in the
original signature with a different phosphosite (S916).
Taken together, Pareto markers are consistently smaller than the original marker, while
three of four also have better separation and relevance scores. The prediction accuracy on the
validation set is identical for all investigated signatures, however, the average probability dis-
tance to the separating SVM hyperplane is slightly higher for the Pareto signatures, suggesting
that the Pareto signatures are more robust when being applied to other classes of related tumor
cell lines.
Conclusions
We and others have previously shown that the identification of response prediction markers
from phosphoproteomics experiments in pre-clinical or clinical settings is possible [9, 10, 38].
These studies sought to identify single signatures of phosphorylation sites maximizing the sep-
aration on the data used for training. Here, we investigated the idea of integrating additional
objectives, such as the relevance with respect to the drug target or the size of a signature, into
the feature selection process. We applied the multi-objective genetic algorithm NSGA-II [24]
to the identification of Pareto-optimal solutions for the prediction of response of NSCLC cell
lines to treatment with dasatinib. Beside separability, we used the proximity of markers to the
main drug target—the Src kinase—and the size of the signature as objectives for optimization.
In total, the algorithm identifies 77 Pareto-optimal solutions, i.e. solutions that are not dom-
inated by any other solution. Each solution corresponds to a phosphorylation signature that
can be used for response prediction. 53 of them had a sufficiently good separation score and
were considered in the following analysis. Clustering of these solutions in feature-space re-
vealed four groups of solutions with similar sets of phosphorylation sites. We used the solution
closest to the centroid of each cluster as representatives of the four Pareto signatures. All four
signatures predicted the response of six breast cancer cell lines that were not used for training
with good accuracy (83%). The same accuracy was also reached by the original 12-marker sig-
nature identified in Klammer et al. [9]. Since NSCLC and breast cancer are often caused by ab-
errations of different signaling pathways, predictive signatures may be expected to differ in
NSCLC and breast cancer. The fact that the four signatures identified here all have a high accu-
racy in NSCLC and breast cancer demonstrates their reliability and, particularly, their
robustness.
The phosphorylation site S1448 on ITGB4 (Uniprot accession: P16144-2; or, equivalently,
S1518 in the canonical sequence P16144-1) is the central feature in all four Pareto signatures.
This is in accordance with the results from Klammer et al. [9], where the same site was ranked
first in the robust feature selection approach. Furthermore, ITGB4 is closely linked to dasati-
nib’s main target SRC via the adapter protein GRB2. Thus, the Pareto marker approach is con-
sistent with the outstanding role of ITGB4 in predicting dasatinib response in cancer cells.
Although it was not in the scope of the study to perform a comprehensive comparison be-
tween many different feature selection approaches applied to various diverse data sets, we com-
pared the Pareto optimization approach to the biomarker discovery workflow established in
the previous publication [9]. The forward feature selection method used there yielded a larger
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signature containing 12 phosphorylation markers, while the incorporation of signature size as
additional objective in the genetic algorithm approach led to relatively small signatures (be-
tween 3 and 7 phosphorylation sites) in the present study. Similarly, optimizing for biological
relevance led to signatures containing many proteins that are directly or indirectly linked to
the Src kinase. More specifically, we used the proximity of the markers to the drug target SRC
as determined in the STRING PPI network as proxy for the biological relevance of the markers.
Despite advances in the determination of protein-protein interactions [39], PPI networks are
still notoriously noisy. We therefore took only interactions into account that had high confi-
dence scores ( 0.9). Moreover, since the PPI network is used only to complement the phos-
phoproteomics data, the effect of false positives on the selection of features will be limited as
long as the corresponding phosphorylations do not exhibit predictive differential regulations.
The four Pareto signatures are characterized by properties that correspond to the objectives
used for optimization. Signature 1 and 3 are relatively small with only three phosphorylation
sites each. On the other hand, signature 4 is larger (7 sites), but has the best separation. Finally,
signature 2 shows the best relevance score, meaning that its marker proteins are interacting
with the drug target SRC either directly or through intermediate proteins. Surprisingly, while
its separation on the training data is the smallest of all four signatures, it yields the highest sep-
aration on the breast cancer cell lines that were used for validation. This hints at the impor-
tance of incorporating network information in general and the relationship to the drug target
in particular for the identification of robust predictive marker, which can be applied to diverse
sets of samples, e.g. breast cancer instead of NSCLC cell lines.
Of course, Pareto optimization is not the only possibility to incorporate network informa-
tion or other kind of additional information into the identification of predictive markers. For
example, Deng, Geng and Ali applied a Bayesian Network model to integrate mass spectrome-
try and microarray data [40]. The top-performing team in the NCI-DREAM drug-sensitivity
prediction challenge applied a nonlinear, probabilistic regression model [11]. These ap-
proaches try to include the different data sources into a unified model, whereas here we model
the different data sources as separate objectives. Although the approaches are based on differ-
ent principles, the aim to integrate additional data sources is the same. Indeed, it would be very
interesting to combine these approaches—for example, by using a Bayesian network as basis
for additional objectives.
We optimized the selected features with respect to the objectives separation, size, and rele-
vance. Naturally, the proposed method can be applied to other objectives. For example, it may
be sensible to include the detectability of marker phosphorylations in immunoassays, the local-
ization of the marker proteins (e.g. cell membrane, nucleus, or cytosol), or the extend of knowl-
edge about the proteins (e.g. number of PubMed abstracts).
Aside from the possibility of incorporating multiple objectives into the selection of the bio-
marker signatures, an even more important advantage of the approach presented here is the
identification of several independent signatures instead of only one. These signatures can be
evaluated post-hoc using additional criteria before a final signature or a set of a few signatures
is selected for further validation experiments.
In summary, we demonstrated the power of Pareto optimization when applied to identifica-
tion of predictive phosphorylation signatures. Naturally, the approach is by no means restrict-
ed to this kind of data and could equally well be applied to other high-dimensional data such as
transcriptomics, genomics, or metabolomics data. Besides optimizing the separation between
two classes, the method allows the consideration of additional objectives. In particular, we
showed that the relation of the marker proteins to the drug target in a protein-protein interac-
tion network can improve the robustness of the prediction when applied to new samples.
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Materials and Methods
Data
The training data comprising the class-I phosphorylation site ratios of 19 NSCLC cell lines rel-
ative to a SuperSILAC spike-in were obtained from Supplemental Table 3 of Klammer et al.
[9]. The validation data for 6 breast cancer cell lines were taken from Supplemental Table 4 of
the same source. Detailed information about the generation of both datasets is provided in the
main article of Klammer et al. [9]. In brief, the dataset contains more than 25,000 class-I phos-
phorylation sites (i.e. sites with high localization confidence), contaminant and reverse data-
base hits were removed, and the normalized ratios (cell line versus SuperSILAC) were
log10-transformed.
Pareto objective functions
Three objectives were considered: signature size, separation and relevance.
Signature size. This objective score is defined by the number of phosphosites in a given
signature. The score is to be minimized.
Separation. This objective focuses on the generalization of the marker. Not only should a
good marker separate the training data, but also unseen data. Thus, an inner leave-one-out
cross validation was performed by employing a support vector machine with linear kernel and
cost parameter C = 1. For each test sample, its distance of to the SVM hyperplane was comput-
ed and the posterior class probability was calculated from a sigmoid model pi ¼ 11þexpðAfiþBÞ,
where pi is the probability of the sample being resistant and fi the SVM output of the respective
training data [41]. Parameter A was determined by optimizing a regularized maximum likeli-
hood problem (see [41] for details); parameter B was fixed to 0, so that points on the separating
hyperplane are assigned a probability of 0.5. The separation objective corresponds to minimi-
zation of the negative minimal probability distanceminiðcið12 piÞ þ 12Þ, where ci is the actual
class of the cell line (sensitive = 1, resistant = −1).
Relevance. This objective deals with the relevance of a signature with respect to the drug
target. Here, the mean distance of the signature’s proteins to the target of the investigated drug
in a protein-protein interaction network (STRING) was calculated. To this end, we calculated
an adjacency matrix using all interactions with a interaction confidence larger than 0.9
(STRING version 9.05 [42]). The remaining edges with interaction confidence scores s ranging
from 0.9 to 0.999 were transformed into a penalty score using the equation ri ¼ 1log10ð1siÞ,
ranging from 0.33 to 1. The function was chosen to get more pronounced differences between
higher and lower confidence scores. Subsequently, the shortest path between each protein in
the signature and the drug target based on the penalties ρ was calculated with the Dijkstra algo-
rithm [43] and the mean distance of all signature proteins was used as objective score.
Pareto optimization
For the detection of the Pareto front, we applied the NSGA-II algorithm. NSGA-II is a fast, elit-
ist multi-objective genetic algorithm [24] that employs the principle of Pareto optimality. In
brief, the algorithm works as follows: First, a random parent population P0 was generated that
consists of N = 200 chromosomes. The representation of the chromosome is binary, i.e. a fea-
ture that is part of the signature is represented by 1, a feature that is not part of the signature by
0. The chromosomes were randomly initialized with 10% of features set to 1. Next, a fitness
value was assigned to each chromosome, which represents the Pareto front the individual was
located on. A fitness value of 1 stands for a solution on the first Pareto front, 2 for a solution on
the second Pareto front, and so forth.
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Subsequently, 5-way-tournament selection, single-point crossover (p = 0.8) and bit flip mu-
tation (p = 0.02) were performed to generate the first offspring generation Q0 (N = 200). To
compile the next parent generation P1, the individuals of P0 and Q0 were combined and the in-
dividuals were sorted according to non-domination (Pareto front 1 . . . F) and within each
front according to the crowding distance (favors individuals that have a large distance to their
neighbors, see [24] for details). Finally, the top N individuals were chosen to become P1, which
ensured elitism.
This procedure was repeated for G generations, where G is a number determined at runtime,
at which the solutions on the first Pareto front do not change for 200 generations in feature
space.
Biomarker discovery workflow
In order to detect multiple signatures based on the 19 NSCLC samples, the phosphorylation
sites were first pre-filtered for missing data, i.e. only class-I sites with at least 2/3 of ratios pres-
ent in each group (responder and non-responder) were considered for further analyses. Next,
the 100 sites that discriminated best between responders and non-responders according to the
MeanRank [31] test were selected, while ensuring that the mean difference of the features be-
tween the two groups was at least 4-fold and only one phosphosite per protein was included.
This pre-selection is necessary to reduce the complexity of the subsequent Pareto optimization.
The 100 top-ranking features were subjected to the NSGA-II algorithm, which aims at detect-
ing Pareto-optimal solutions based on the three objective functions (size, separation,
relevance).
After convergence, the results were filtered for solutions that were located on the first Pareto
front. Since many of them were very similar and only differ in very few features, hierarchical
clustering with Ward’s method was applied on the binary solution vectors to detect clusters of
similar features. Subsequently, the solutions that had the smallest Euclidean distance to the
cluster centroids were taken as final Pareto signatures. If more than one solution had the small-
est distance, the one with the better separation score was preferred.
Biomarker validation
For each Pareto signature, a support vector machine with linear kernel and cost parameter
C = 1 was trained. These SVMs are the final predictors and can be used to predict new samples.
To validate the signatures, we used phosphorylation site data of the six breast cancer samples.
Prior to prediction, missing values were imputed by the mean of the training data class means
(for details see [9]). Subsequently, the responsiveness of the six samples was predicted with
each of the final predictors.
Supporting Information
S1 Fig. Example of a Pareto front in a minimization problem. The plot shows different solu-
tions of a toy example. Blue points are feasible solutions, where those that are not dominated
by any other solution are referred to as Pareto points (dark-blue). Together they form the Pa-
reto front. The points in the lower left area represent solutions that are desired but not feasible
(yellow/red).
(TIFF)
Identification of Predictive Pareto Biomarker Signatures
PLOS ONE | DOI:10.1371/journal.pone.0128542 June 17, 2015 13 / 16
Acknowledgments
The authors wish to thank their colleagues at Evotec for fruitful discussions and support. This
work is based on a project supported by the Federal German Ministry of Education and Re-
search (0315011).
Author Contributions
Conceived and designed the experiments: DH CS. Performed the experiments: MK JND. Ana-
lyzed the data: MK. Wrote the paper: MK JND CS.
References
1. Passeron T, Lacour JP, Allegra M, Ségalen C, Deville A, Thyss A, et al. (2011) Signalling and chemo-
sensitivity assays in melanoma: Is mutated status a prerequisite for targeted therapy? Experimental
Dermatology 20: 1030–1032. doi: 10.1111/j.1600-0625.2011.01385.x PMID: 22092579
2. Huang F, Reeves K, Han X, Fairchild C (2007) Identification of candidate molecular markers predicting
sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer research 67.5: 2226–
2238. doi: 10.1158/0008-5472.CAN-06-3633 PMID: 17332353
3. Dressman H, Berchuck A, Chan G (2007) An integrated genomic-based approach to individualized
treatment of patients with advanced-stage ovarian cancer. Journal of Clinical Oncology 25: 517–525.
doi: 10.1200/JCO.2006.06.3743 PMID: 17290060
4. Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, et al. (2006) Global, In Vivo, and Site-
Specific Phosphorylation Dynamics in Signaling Networks. Cell 127: 635–648. doi: 10.1016/j.cell.
2006.09.026 PMID: 17081983
5. Macek B, Mann M, Olsen J (2009) Global and site-specific quantitative phosphoproteomics: principles
and applications. Annu Rev Pharmacol Toxicol 49: 199–221. PMID: 18834307
6. Schaab C (2011) Analysis of phosphoproteomics data. Methods in molecular biology (Clifton, NJ) 696:
41–57.
7. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411: 355–365. doi: 10.1038/
35077225 PMID: 11357143
8. Kaminska B (2005) MAPK signalling pathways as molecular targets for anti-inammatory therapy–from
molecular mechanisms to therapeutic benefits. Biochimica et biophysica acta 1754: 253–262. doi: 10.
1016/j.bbapap.2005.08.017 PMID: 16198162
9. Klammer M, Kaminski M, Zedler A, Oppermann F, Blencke S, Marx S, et al. (2012) Phosphosignature
Predicts Dasatinib Response in Non-small Cell Lung Cancer. Molecular & Cellular Proteomics 11:
651–668. doi: 10.1074/mcp.M111.016410
10. Schaab C, Oppermann FS, Klammer M, Pfeifer H, Tebbe A, Oellerich T, et al. (2014) Global phospho-
proteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment
of acute myeloid leukemia with quizartinib. Leukemia 28: 716–9. doi: 10.1038/leu.2013.347 PMID:
24247654
11. Costello JC, Heiser LM, Georgii E, Gönen M, Menden MP, Wang NJ, et al. (2014) A community effort to
assess and improve drug sensitivity prediction algorithms. Nature biotechnology 32: 1202–1212. doi:
10.1038/nbt.2877 PMID: 24880487
12. Cun Y, Fröhlich H (2012) Prognostic gene signatures for patient stratification in breast cancer—accura-
cy, stability and interpretability of gene selection approaches using prior knowledge on protein-protein
interactions. BMC Bioinformatics 13: 69. doi: 10.1186/1471-2105-13-69 PMID: 22548963
13. Zhu Y, Shen X, PanW (2009) Network-based support vector machine for classification of microarray
samples. BMC bioinformatics 10 Suppl 1: S21. doi: 10.1186/1471-2105-10-S1-S21 PMID: 19208121
14. Roy J, Winter C, Isik Z, Schroeder M (2014) Network information improves cancer outcome prediction.
Briefings in bioinformatics 15: 612–625. doi: 10.1093/bib/bbs083 PMID: 23255167
15. Winter C, Kristiansen G, Kersting S, Roy J, Aust D, Knösel T, et al. (2012) Google goes cancer: Improv-
ing outcome prediction for cancer patients by network-based ranking of marker genes. PLoS Computa-
tional Biology 8: e1002511. doi: 10.1371/journal.pcbi.1002511 PMID: 22615549
16. Deb K (2001) Multi-Objective Optimization using Evolutionary Algorithms. Chichester, West Sussex,
England: JohnWiley & Sons, Ltd.
17. Nicolaou C, Brown N (2013) Multi-objective optimization methods in drug design. Drug Discovery
Today: Technologies 10: e427–e435. doi: 10.1016/j.ddtec.2013.02.001 PMID: 24050140
Identification of Predictive Pareto Biomarker Signatures
PLOS ONE | DOI:10.1371/journal.pone.0128542 June 17, 2015 14 / 16
18. Gronwald W, Hohm T, Hoffmann D (2008) Evolutionary Pareto-optimization of stably folding peptides.
BMC bioinformatics 9: 109. doi: 10.1186/1471-2105-9-109 PMID: 18284690
19. Rajapakse JC, Mundra PA (2013) Multiclass gene selection using Pareto-fronts. IEEE/ACM transac-
tions on computational biology and bioinformatics / IEEE, ACM 10: 87–97. doi: 10.1109/TCBB.2013.1
PMID: 23702546
20. Xue B, Zhang M, BrowneWN (2013) Particle swarm optimization for feature selection in classification:
a multi-objective approach. IEEE transactions on cybernetics 43: 1656–71. doi: 10.1109/TSMCB.
2012.2227469 PMID: 24273143
21. Knowles J, Corne D (1999) The Pareto archived evolution strategy: A new baseline algorithm for Pareto
multiobjective optimisation. In: Proceedings of the 1999 Congress on Evolutionary Computation, CEC
1999. volume 1, pp. 98–105. doi: 10.1109/CEC.1999.781913
22. Corne DW, Knowles JD, Oates MJ (2000) The Pareto Envelope-based Selection Algorithm for Multiob-
jective Optimization. Decision Analysis 1917: 839–848.
23. Zitzler E, Laumanns M, Thiele L (2001) SPEA2: Improving the Strength Pareto Evolutionary Algorithm.
In: Evolutionary Methods for Design Optimization and Control with Applications to Industrial
Problems. pp. 95–100.
24. Deb K, Pratap A, Agarwal S, Meyarivan T, Member A (2002) A fast and elitist multiobjective genetic al-
gorithm: NSGA-II. IEEE Transactions on Evolutionary Computation 6: 182–197. doi: 10.1109/4235.
996017
25. Beume N, Naujoks B, Emmerich M (2007) SMS-EMOA: Multiobjective selection based on dominated
hypervolume. European Journal of Operational Research 181: 1653–1669. doi: 10.1016/j.ejor.2006.
08.008
26. Konak A, Coit DW, Smith AE (2006) Multi-objective optimization using genetic algorithms: A tutorial.
Reliability Engineering and System Safety 91: 992–1007. doi: 10.1016/j.ress.2005.11.018
27. Coello CAC (2006) Evolutionary multi-objective optimization: a historical view of the field. IEEE compu-
tational intelligence magazine: 28–36.
28. Johnson F, Saigal B, Talpaz M, Donato N (2005) tyrosine kinase inhibitor suppresses invasion and in-
duces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and nonsmall cell
lung. Clinical Cancer Research 3: 6924–6932. doi: 10.1158/1078-0432.CCR-05-0757
29. Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, et al. (2007) Dasatinib inhibits
migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma
cells dependent on SRC kinase for survival. Cancer research 67: 2800–8. doi: 10.1158/0008-5472.
CAN-06-3469 PMID: 17363602
30. Buettner R, Mesa T, Vultur A, Lee F, Jove R (2008) Inhibition of Src family kinases with dasatinib blocks
migration and invasion of human melanoma cells. Molecular cancer research: MCR 6: 1766–74. doi:
10.1158/1541-7786.MCR-08-0169 PMID: 19010823
31. Klammer M, Dybowski JN, Hoffmann D, Schaab C (2014) Identification of significant features by the
global mean rank test. PLoS ONE 9: e104504. doi: 10.1371/journal.pone.0104504 PMID: 25119995
32. Nicolaou CA, Apostolakis J, Pattichis CS (2009) De novo drug design using multiobjective evolutionary
graphs. Journal of Chemical Information and Modeling 49: 295–307. doi: 10.1021/ci800308h PMID:
19434831
33. Dutta U, Shaw LM (2008) A Key Tyrosine (Y1494) in the beta4 Integrin Regulates Multiple Signaling
Pathways Important for Tumor Development and Progression. Cancer research 68: 8779–8787. doi:
10.1158/0008-5472.CAN-08-2125 PMID: 18974120
34. Tagliabue E, Ghirelli C, Squicciarini P, Aiello P, Colnaghi MI, Ménard S (1998) Prognostic value of
alpha 6 beta 4 integrin expression in breast carcinomas is affected by laminin production from tumor
cells. Clinical cancer research: an official journal of the American Association for Cancer Research 4:
407–10.
35. Lu S, Simin K, Khan A, Mercurio AM (2008) Analysis of integrin beta4 expression in human breast can-
cer: association with basal-like tumors and prognostic significance. Clinical cancer research: an official
journal of the American Association for Cancer Research 14: 1050–8. doi: 10.1158/1078-0432.CCR-
07-4116
36. VanWaes C, Kozarsky KF, Warren AB, Kidd L, Paugh D, Liebert M, et al. (1991) The A9 antigen asso-
ciated with aggressive human squamous carcinoma is structurally and functionally similar to the newly
defined integrin alpha 6 beta 4. Cancer research 51: 2395–402. PMID: 1750876
37. Chung BM, Dimri M, George M, Reddi AL, Chen G, Band V, et al. (2009) The role of cooperativity with
Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mu-
tants. Oncogene 28: 1821–1832. doi: 10.1038/onc.2009.31 PMID: 19305428
Identification of Predictive Pareto Biomarker Signatures
PLOS ONE | DOI:10.1371/journal.pone.0128542 June 17, 2015 15 / 16
38. Andersen J, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen A, et al. (2010) Pathway-based
identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibi-
tors. Science translational medicine 2: 43ra55. doi: 10.1126/scitranslmed.3001065
39. Keilhauer EC, Hein MY, Mann M (2014) Accurate protein complex retrieval by affinity enrichment MS
rather than affinity purification MS. Molecular & cellular proteomics: MCP 14: 120–135.
40. Deng X, Geng H, Ali HH (2007) Cross-platform analysis of cancer biomarkers: A Bayesian network ap-
proach to incorporating mass spectrometry and microarray data. Cancer Informatics 3: 183–202.
PMID: 19455243
41. Lin HT, Lin CJ, Weng RC (2007) A note on Platt’s probabilistic outputs for support vector machines. Ma-
chine Learning 68: 267–276. doi: 10.1007/s10994-007-5018-6
42. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al. (2013) STRING v9.1:
Protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Research
41. doi: 10.1093/nar/gks1094
43. Dijkstra EW (1959) A note on two problems in connexion with graphs. Numerische Mathematik 1: 269–
271. doi: 10.1007/BF01386390
Identification of Predictive Pareto Biomarker Signatures
PLOS ONE | DOI:10.1371/journal.pone.0128542 June 17, 2015 16 / 16
